Author Archives: Janet Stewart, MSc

Some Patients with Hydralazine-related AAV Develop Advanced Kidney Disease, Study Finds

Some patients with ANCA-associated vasculitis (AAV) caused by hydralazine — a medication used to treat high blood pressure — develop end-stage kidney disease, even after discontinuing the medicine and receiving immunosuppressive therapy, a small study found. The risk for hydralazine-induced AAV appears to be higher among African-Americans, according to the Johns Hopkins…

GSK’s Nucala Approved by FDA as Add-on Therapy for EGPA Patients

The U.S. Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on to standard care for treating eosinophilic granulomatosis with polyangiitis (EGPA), previously called Churg-Strauss syndrome. “Patients suffering from EGPA too often face a frustrating journey from a delay in receiving a proper diagnosis to having…